Astellas Gene Therapies

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative ... DevelopingTherapiesToTransformLives AstellasGeneTherapiesisanAstellasCenterofExcellencedevelopinggeneticmedicineswiththepotentialtodelivertransformativevalueforpatients. Watchthestoryofafamilyaffectedbyaneuromusculardisease INNOVATIVETHERAPIES Ourinvestigationaltherapiestargetrarediseasesthroughthreemodalities:genereplacement,exonskippinggenetherapyandvectorizedRNAknockdown.WeareleveragingAstellas’globalresources,industryleadershipinimmunebiology,anddeepscientificexpertisetoexpandourreachanddevelopvaluablenewgeneticmedicines forpatientsaroundtheworld. X‐linkedMyotubularMyopathy AT132 GenereplacementtherapycandidatetotreatXLMTM,adiseasecausedbymutationsintheMTM1gene,whichencodestheproteinmyotubularin PompeDisease AT845 GenereplacementtherapycandidatetotreatPompediseasecausedbymutationsinthegeneencodingthelysosomalenzymeGAA MyotonicDystrophyType1 AT466 AAV-antisensecandidatetotreatDM1causedbyamutationintheDMPKgene,resultingintheaccumulationoftoxicDMPKRNAinaffectedcells. COURAGEOUSPATIENTS Wedependoncourageouspatientsandtheirfamiliestoadvanceourinvestigationaltherapies.Ourpatientcommunitiesareimportantpartnersandcollaborators,informingourclinicaltrialprogramsanddrugdevelopmentprocess. LEARNMORE STATE-OF-THE-ARTFACILITIES Thescienceofgeneticmedicinesiscomplex.Ourrobustcapabilitiesandindustryleadingmanufacturingfacilitiesputusattheforefrontofdevelopinginnovativetherapies. Readmore OURPEOPLE Wetakeprideinourmissiontodeveloptransformativegeneticmedicinestopatientsaroundtheworld.Ourexperiencedteamhasthepassionanddrivetoaccomplishourgoalofhelpingpatientswithlife-threateningdiseases.Ifyou’relookingforafast-pacedworkenvironmentwhereemployeeswholeheartedlyembodya“GetStuffDone”attitude,you’llfitrightin. MEETOURTEAM JOINOURTEAM       COMPANYUPDATES   PressReleases Jul26,2022AstellasUnveilsPlanstoOpenNewBiotechCampusinSouthSanFrancisco Jun27,2022AstellasAnnouncesFDAUpdateontheFORTISClinicalTrialofAT845inAdultswithLate-OnsetPompeDisease Jun08,2022AstellasCelebratestheOpeningofItsNewLarge-ScaleGeneTherapyManufacturingFacilityinNorthCarolina ViewAllNews @AstellasGeneTx Learnmoreaboutwhatwe’redoingtobecometheleaderinthedevelopmentandcommercializationofinnovativegeneticmedicines,thepeoplewhomakeuswhoweare,andtheexcitingjobopportunitiesavailablebyfollowingusonLinkedIn. followusontwitter> Learnmoreaboutwhatwe’redoingtobecometheleaderinthedevelopmentandcommercializationofinnovativegeneticmedicinestotreatseriousrareneuromusculardiseases,thepeoplewhomakeitgreatandtheexcitingjobopportunitiesavailablebyfollowingusonLinkedIn. followusonlinkedin>     Menu